정밀 종양학 시장(2026-2030년)

The global precision oncology market is forecasted to grow by USD 71113.5 mn during 2025-2030, accelerating at a CAGR of 9.5% during the forecast period. The report on the global precision oncology market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by technological advancements in next-generation sequencing and molecular diagnostics, integration of ai and ml in therapeutic decision-making, escalating global cancer prevalence and transition to value-based healthcare models.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global precision oncology market is segmented as below:

By Type

• Therapeutics
• Diagnostics
• Companion and monitoring services

By End-User

• Hospitals and diagnostic laboratories
• Pharmaceutical and biotechnology companies
• Academic and research institutes
• Healthcare data companies

By Technology

• Genomic sequencing and bioinformatics
• Biomarker discovery
• Molecular imaging
• Data analytics and AI

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Russia
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the proliferation of multi-cancer early detection and liquid biopsy integration as one of the prime reasons driving the global precision oncology market growth during the next few years. Also, acceleration of ai and computational oncology in personalized drug discovery and expansion of precision immunotherapy and targeted delivery systems in emerging markets will lead to sizable demand in the market.

The report on the global precision oncology market covers the following areas:

• Global precision oncology market sizing
• Global precision oncology market forecast
• Global precision oncology market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global precision oncology market vendors that include Agilent Technologies Inc., Bio Rad Laboratories Inc., Caris Life Sciences, Exact Sciences Corp., Foundation Medicine Inc., Guardant Health Inc., Illumina Inc., Laboratory Holdings Inc., Myriad Genetics Inc., Natera Inc., NeoGenomics Laboratories Inc., Pillar Biosciences Inc., Predicine Inc., QIAGEN N.V., Quest Diagnostics Inc., SOPHiA GENETICS, Sysmex Corp., Tempus AI Inc., Thermo Fisher Scientific Inc., Velsera Inc. Also, the global precision oncology market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Type
  • Executive Summary - Chart on Market Segmentation by End-user
  • Executive Summary - Chart on Market Segmentation by Technology
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Precision Oncology Market 2020 - 2024
  • Historic Market Size - Data Table on Global Precision Oncology Market 2020 - 2024 ($ million)
• 5.2 Type segment analysis 2020 - 2024
  • Historic Market Size - Type Segment 2020 - 2024 ($ million)
• 5.3 End-user segment analysis 2020 - 2024
  • Historic Market Size - End-user Segment 2020 - 2024 ($ million)
• 5.4 Technology segment analysis 2020 - 2024
  • Historic Market Size - Technology Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 Impact of AI on Global Precision Oncology Market
• 6.2 Impact of geopolitical conflicts on Global Precision Oncology Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Type

• 8.1 Market segments
• 8.2 Comparison by Type
• 8.3 Therapeutics - Market size and forecast 2025-2030
• 8.4 Diagnostics - Market size and forecast 2025-2030
• 8.5 Companion and monitoring services - Market size and forecast 2025-2030
• 8.6 Market opportunity by Type
  • Market opportunity by Type ($ million)

9 Market Segmentation by End-user

• 9.1 Market segments
• 9.2 Comparison by End-user
• 9.3 Hospitals and diagnostic laboratories - Market size and forecast 2025-2030
• 9.4 Pharmaceutical and biotechnology companies - Market size and forecast 2025-2030
• 9.5 Academic and research institutes - Market size and forecast 2025-2030
• 9.6 Healthcare data companies - Market size and forecast 2025-2030
• 9.7 Market opportunity by End-user
  • Market opportunity by End-user ($ million)

10 Market Segmentation by Technology

• 10.1 Market segments
• 10.2 Comparison by Technology
• 10.3 Genomic sequencing and bioinformatics - Market size and forecast 2025-2030
• 10.4 Biomarker discovery - Market size and forecast 2025-2030
• 10.5 Molecular imaging - Market size and forecast 2025-2030
• 10.6 Data analytics and AI - Market size and forecast 2025-2030
• 10.7 Market opportunity by Technology
  • Market opportunity by Technology ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
  • 12.4.7 Russia - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 Japan - Market size and forecast 2025-2030
  • 12.5.3 India - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Indonesia - Market size and forecast 2025-2030
  • 12.5.6 Thailand - Market size and forecast 2025-2030
  • 12.5.7 Singapore - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Australia - Market size and forecast 2025-2030
  • 12.6.5 Turkey - Market size and forecast 2025-2030
  • 12.6.6 South Africa - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Technological advancements in next-generation sequencing and molecular diagnostics
  • Integration of AI and ML in therapeutic decision-making
  • Escalating global cancer prevalence and transition to value-based healthcare models
• 13.2 Market challenges
  • Prohibitive costs of advanced molecular profiling and disparities in reimbursement frameworks
  • Data privacy concerns and increasing complexity of genomic information security
  • Critical shortage of specialized clinical personnel and bioinformatics expertise
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Proliferation of multi-cancer early detection and liquid biopsy integration
  • Acceleration of AI and computational oncology in personalized drug discovery
  • Expansion of precision immunotherapy and targeted delivery systems in emerging markets

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Agilent Technologies Inc.
  • Agilent Technologies Inc. - Overview
  • Agilent Technologies Inc. - Business segments
  • Agilent Technologies Inc. - Key news
  • Agilent Technologies Inc. - Key offerings
  • Agilent Technologies Inc. - Segment focus
  • SWOT
• 15.5 Bio Rad Laboratories Inc.
  • Bio Rad Laboratories Inc. - Overview
  • Bio Rad Laboratories Inc. - Business segments
  • Bio Rad Laboratories Inc. - Key news
  • Bio Rad Laboratories Inc. - Key offerings
  • Bio Rad Laboratories Inc. - Segment focus
  • SWOT
• 15.6 Caris Life Sciences
  • Caris Life Sciences - Overview
  • Caris Life Sciences - Product / Service
  • Caris Life Sciences - Key offerings
  • SWOT
• 15.7 Guardant Health Inc.
  • Guardant Health Inc. - Overview
  • Guardant Health Inc. - Product / Service
  • Guardant Health Inc. - Key offerings
  • SWOT
• 15.8 Illumina Inc.
  • Illumina Inc. - Overview
  • Illumina Inc. - Business segments
  • Illumina Inc. - Key news
  • Illumina Inc. - Key offerings
  • Illumina Inc. - Segment focus
  • SWOT
• 15.9 Laboratory Holdings Inc.
  • Laboratory Holdings Inc. - Overview
  • Laboratory Holdings Inc. - Business segments
  • Laboratory Holdings Inc. - Key offerings
  • Laboratory Holdings Inc. - Segment focus
  • SWOT
• 15.10 Myriad Genetics Inc.
  • Myriad Genetics Inc. - Overview
  • Myriad Genetics Inc. - Product / Service
  • Myriad Genetics Inc. - Key offerings
  • SWOT
• 15.11 Natera Inc.
  • Natera Inc. - Overview
  • Natera Inc. - Business segments
  • Natera Inc. - Key offerings
  • Natera Inc. - Segment focus
  • SWOT
• 15.12 QIAGEN N.V.
  • QIAGEN N.V. - Overview
  • QIAGEN N.V. - Product / Service
  • QIAGEN N.V. - Key offerings
  • SWOT
• 15.13 Quest Diagnostics Inc.
  • Quest Diagnostics Inc. - Overview
  • Quest Diagnostics Inc. - Business segments
  • Quest Diagnostics Inc. - Key offerings
  • Quest Diagnostics Inc. - Segment focus
  • SWOT
• 15.14 SOPHiA GENETICS
  • SOPHiA GENETICS - Overview
  • SOPHiA GENETICS - Product / Service
  • SOPHiA GENETICS - Key offerings
  • SWOT
• 15.15 Sysmex Corp.
  • Sysmex Corp. - Overview
  • Sysmex Corp. - Business segments
  • Sysmex Corp. - Key news
  • Sysmex Corp. - Key offerings
  • Sysmex Corp. - Segment focus
  • SWOT
• 15.16 Tempus AI Inc.
  • Tempus AI Inc. - Overview
  • Tempus AI Inc. - Product / Service
  • Tempus AI Inc. - Key offerings
  • SWOT
• 15.17 Thermo Fisher Scientific Inc.
  • Thermo Fisher Scientific Inc. - Overview
  • Thermo Fisher Scientific Inc. - Business segments
  • Thermo Fisher Scientific Inc. - Key news
  • Thermo Fisher Scientific Inc. - Key offerings
  • Thermo Fisher Scientific Inc. - Segment focus
  • SWOT
• 15.18 Velsera Inc
  • Velsera Inc - Overview
  • Velsera Inc - Product / Service
  • Velsera Inc - Key offerings
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations